ArticleJournal of addiction medicine2026
Opioid Use Disorder Care Presentations After High-deductible Health Plan Enrollment.
Article in Journal of addiction medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveDetermine whether employer-mandated transitions from low- to high-deductible health plans (HDHPs) are associated with delays in opioid use disorder (OUD)-related care presentations. Cost-sharing may negatively impact timely diagnosis and treatment of OUD.
methodsUsing 2003-2017 national commercial insurance claims data, we used a matched time-to-event and difference-in-differences design to examine the association between employer-mandated transitions from low to HDHPs on OUD-related care presentations. Study group included 574,058 adults aged 18-64 years continuously enrolled in low-deductible (<$500) health plans during a baseline year followed by up to 4 years in HDHPs (≥$1000) after an employer-mandated transition (exposure). Control group included 4,386,636 adults contemporaneously enrolled in low-deductible plans matched on employee and employer characteristics. Outcomes included first OUD-related office visit, buprenorphine pharmacy fill, and OUD-related high-acuity visit. The secondary outcome was the yearly number of high-acuity care days.
resultsAfter an employer-mandated HDHP transition, there were no differences in time-to-first OUD-related office visit (HR, 1.02, 95% CI: 0.94, 1.11) or buprenorphine fill (HR, 1.05, 95% CI: 0.97-1.13) in the HDHP versus control cohort. In contrast, the HDHP transition was associated with delays in time-to-first OUD-related high-acuity visits compared with control members (HR 0.86, 95% CI: 0.79-0.93). HDHP members experienced a 37.4% (95% CI: -57.8, -17.0) relative reduction in high-acuity care days relative to the control group from baseline to follow-up.
conclusionsEmployer-mandated transitions to HDHPs were associated with delays and reductions in OUD-related high-acuity presentations. Such delays and reductions in timely OUD care could lead to adverse health outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.